Gilead Sciences (GILD) Current Deferred Revenue (2009 - 2016)

Gilead Sciences (GILD) has 8 years of Current Deferred Revenue data on file, last reported at $202.0 million in Q4 2016.

• For the quarter ending Q4 2016, Current Deferred Revenue fell 54.09% year-over-year to $202.0 million; the trailing twelve-month figure through Dec 2016 stood at $202.0 million (down 54.09% YoY), and the FY2016 full-year result was $202.0 million, down 54.09% from the prior year.
• Current Deferred Revenue for Q4 2016 stood at $202.0 million, down from $361.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $529.0 million in Q1 2016 and bottomed at $93.7 million in Q2 2012.
• The 5-year median for Current Deferred Revenue is $126.8 million (2013), against an average of $214.2 million.
• The widest annual swing landed in 2015, when Current Deferred Revenue surged 296.72%; it then slumped 54.09% in 2016.
• A 5-year view of Current Deferred Revenue shows it stood at $103.2 million in 2012, then increased by 7.6% to $111.0 million in 2013, then rose by 20.72% to $134.0 million in 2014, then soared by 228.36% to $440.0 million in 2015, then plunged by 54.09% to $202.0 million in 2016.
• The last three Current Deferred Revenue figures came in at $202.0 million (Q4 2016), $361.0 million (Q3 2016), and $345.0 million (Q2 2016), per Business Quant data.

Peer Comparison